Patent intelligence · US
US 9446021
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
Patent details — US 9446021
- Jurisdiction
- US
- Status
- granted
- Grant date
- Sep 20, 2016
- Expiration
- Sep 15, 2036
- Applicant
- Dogwood Pharmaceuticals, Inc.
- Claims
- 15
- CPC classes
- A61K, A61K31/18, A61K31/395, A61K31/409
Quick answer
US 9446021 (Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof) is held by Dogwood Pharmaceuticals, Inc.. Status: granted. Granted Sep 20, 2016. Expires Sep 15, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Dogwood Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/18, A61K31/395, A61K31/409, A61K31/435, A61K31/4545
More from Dogwood Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 9120754
Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
granted -
US 8349848
Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors
granted -
US 8293720
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
granted -
US 8263762
Alkoxy-carbonyl-amino-alkynyl-adenosine compounds and derivatives thereof as A2AR agonists
granted -
US 8258142
Substituted 8-[6-amino-3-pyridyl]xanthines
granted -
US 8252767
Substituted 4-{3-[6-amino-9-(3, 4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
granted
Frequently asked questions
What is US patent 9446021?
US 9446021 (Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof) is held by Dogwood Pharmaceuticals, Inc.. Status: granted. Granted Sep 20, 2016. Expires Sep 15, 2036 (10 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 9446021?
Dogwood Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 7 pharmaceutical patents for this assignee.
When does US 9446021 expire?
Our index shows an expiration date of Sep 15, 2036 (10 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.